The first trial of CIM331, a humanized antihuman interleukin‐31 receptor A antibody,in healthy volunteers and patients with atopic dermatitis to evaluate safety,tolerability and pharmacokinetics of a single dose in a randomized,double‐blind,placebo‐controlled study |
| |
| Authors: | O. Nemoto M. Furue H. Nakagawa M. Shiramoto R. Hanada S. Matsuki S. Imayama M. Kato I. Hasebe K. Taira M. Yamamoto R. Mihara K. Kabashima T. Ruzicka J. Hanifin Y. Kumagai |
| |
| Affiliation: | 1. Kojinkai, Kita13‐Jo Naika‐Hifuka Clinic, Hokkaido, Japan;2. Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;3. Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan;4. Medical Co. LTA Hakata Clinic, Fukuoka, Japan;5. Medical Co. LTA Sumida Hospital, Tokyo, Japan;6. Medical Co. LTA Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan;7. Translational Clinical Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan;8. Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan;9. Department of Dermatology and Allergology, Ludwig‐Maximilian‐University Munich, Munich, Germany;10. Department of Dermatology, Oregon Health and Science University, Portland, OR, U.S.A;11. Kitasato University School of Medicine, Kitasato Clinical Research Center, Kanagawa, Japan |
| |
| Abstract: | |
| |
| Keywords: | |
|
|
